Oral semaglutide adequate glycaemia control with safe cardiovascular profile
Abdulaziz Abdulrahman A. Bedaiwi, Marwan Fahad H Altemani, Nadia Abdullah M Alzahrani, Ali Khaled A Alghannami, Maram Ali S Jarallah, Razan Faisal M Aljohani, Fahad Saad M Alsuhaymi, Sultan Abdullah M. Alamri, Saud Abdulrahman S Alghamdi, Wasan Suwailem S Albalawi, Abdulelah Hamdan K Alonizei, Abdulmajeed Faisal A Albalawi, Mohammed Saad M Alnawmasi, Omniyyah Ahmed Alnahyah, Rawabi Talal S Aljayani, Ibrahim Mahmoud Ajwah, Hazem Radi Rayyan
Abstract
Background
Type 2 diabetes is a chronic and progressive disease that associated with series complication such as major adverse cardiovascular events. Adequate glycaemic control proven to reduce this risk. Orally administered semaglutide promising medication in managing patient with type 2 diabetes.
Aims
To assess the cardiovascular safety and efficacy of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes.
Methods
Pub Med, Google Scholar, and EBSCO databases were systematically search for relevant articles. The terms diabetes, Glucagon-like peptide, semaglutide were used. Out of hundred twenty-two records, only four fulfilled the inclusion criteria.
Results
Four placebo-controlled studies with oral semaglutide were included. Single study concern about the cardiovascular safety of oral semaglutide and showed that, compared with placebo, semaglutide was not associated with increased in the cardiovascular events. On the other hand, the remaining trials shown that, semaglutide can effectively control the blood glucose as evident by reduction in HA1c.
Conclusion
Oral semaglutide can effectively and safely lower blood glucose without increase in the major adverse cardiovascular events (MACE).
Full Text:
Type 2 diabetes is a chronic and progressive disease that associated with series complication such as major adverse cardiovascular events. Adequate glycaemic control proven to reduce this risk. Orally administered semaglutide promising medication in managing patient with type 2 diabetes.
Aims
To assess the cardiovascular safety and efficacy of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes.
Methods
Pub Med, Google Scholar, and EBSCO databases were systematically search for relevant articles. The terms diabetes, Glucagon-like peptide, semaglutide were used. Out of hundred twenty-two records, only four fulfilled the inclusion criteria.
Results
Four placebo-controlled studies with oral semaglutide were included. Single study concern about the cardiovascular safety of oral semaglutide and showed that, compared with placebo, semaglutide was not associated with increased in the cardiovascular events. On the other hand, the remaining trials shown that, semaglutide can effectively control the blood glucose as evident by reduction in HA1c.
Conclusion
Oral semaglutide can effectively and safely lower blood glucose without increase in the major adverse cardiovascular events (MACE).
PDF